Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4Y0 | ISIN: KYG0028A1085 | Ticker-Symbol: 8ZD
Frankfurt
25.04.25
09:59 Uhr
0,835 Euro
-0,025
-2,91 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ABBISKO CAYMAN LTD Chart 1 Jahr
5-Tage-Chart
ABBISKO CAYMAN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3940,47407:00

Aktuelle News zur ABBISKO CAYMAN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS1
17.04.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - AMENDMENTS TO THE POST-IPO RSU SCHEME AND THE POST-IPO SHARE OPTION SCHEME1
15.04.ABBISKO-B (02256): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT1
15.04.ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ...1
15.04.ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ...-
15.04.ABBISKO-B (02256): 2024 ANNUAL REPORT1
10.04.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
01.04.Merck Group pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win28
ABBISKO CAYMAN Aktie jetzt für 0€ handeln
01.04.Abbisko Says Merck Exercised Option For Global Rights Of Pimicotinib577KENILWORTH (NJ) (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0...
► Artikel lesen
01.04.ABBISKO-B (02256): INSIDE INFORMATION - ABBISKO THERAPEUTICS ANNOUNCES MERCK'S EXERCISE OF GLOBAL OPTION FOR PIMICOTINIB UNDER THE LICENSING AGREEMENT3
26.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE CDE FOR ABSK061, A HIGHLY SELECTIVE FGFR2/3 INHIBITOR, FOR THE TREATMENT OF ACHONDROPLASIA1
24.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS AND ALLIST ENTER INTO A COOPERATION AGREEMENT TO EXPLORE ABSK043 IN COMBINATION GLECIRASIB ...2
13.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ...1
12.03.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS1
06.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR, FROM THE CHINA CDE2
04.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ...-
04.03.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS 1
03.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE-
03.03.ABBISKO-B (02256): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; (2) CHANGE IN USE OF NET PROCEEDS; (3) INSIDE INFORMATION; AND ...1
28.02.ABBISKO-B (02256): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1